Clinical Trials

EndocrineNETOther solid neoplasmThoracic

18 enrolled

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT02787642 2026-02-25

RADIOSARP

41 enrolled 15 charts

Sarcoma

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

49 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Ewing

NCT05240898 2025-12-18

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

116 enrolled

Advanced Solid Tumors

NCT03109080 2025-11-24

RadioPARP

24 enrolled

Radiation Injuries, Triple Negative Breast Neoplasms

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

50 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

Triple Negative Metastatic Breast Cancer

NCT04236414 2025-04-04

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

16 enrolled

Neoplasms

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

26 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

70 enrolled 13 charts

Breast Neoplasms, Ovarian Neoplasms

NCT02338622 2024-09-26

ComPAKT

60 enrolled

Advanced Cancer

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Classical hematologyGynecologic

98 enrolled

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00782574 2023-12-21

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

57 enrolled

Advanced Solid Tumors

NCT00535353 2023-08-04

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

26 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02898207 2023-04-26

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

28 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01921140 2022-11-22

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

60 enrolled

Neoplasms

NCT02588105 2022-09-19

AToM

84 enrolled

Advanced Solid Tumours

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

29 enrolled

Solid Tumor

NCT03022409 2021-08-10

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02227082 2021-08-04

Olaparib and Radiotherapy in Inoperable Breast Cancer

7 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

BreastGastrointestinalGenitourinaryGynecologicLymphoid

49 enrolled

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02398058 2021-04-14

TOMAS

50 enrolled

Sarcoma

Bone Neoplasms, Sarcoma

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

118 enrolled

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

3 enrolled

Triple Negative Breast Neoplasms

NCT02121990 2020-08-21

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

17 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

77 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT02511795 2019-11-07

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

128 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02093351 2019-10-02

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

79 enrolled 35 charts

Neoplasms

NCT01758731 2019-09-23

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

17 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Smoking

NCT02324998 2019-08-29

CaNCaP03

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

36 enrolled 24 charts

Advanced Solid Tumours

NCT02418624 2019-01-16

REVIVAL

BreastClassical hematologyGynecologic

25 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT00678132 2018-07-05

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

23 enrolled

Neoplasms

NCT00707707 2018-03-06

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

19 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01390571 2018-02-05

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

34 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01813474 2018-01-16

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

23 enrolled 15 charts

Neoplasms

NCT01851265 2017-08-28

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

32 enrolled

Neoplasms

NCT01296763 2016-03-22

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

18 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00710268 2015-01-14

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

18 enrolled

Neoplasm Metastasis

NCT00515866 2013-12-20

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

68 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

48 enrolled

Malignant Solid Tumors

NCT00572364 2009-08-20

Open Label, Dose Escalation Phase I Study of AZD2281

18 enrolled

Neoplasms

NCT00516802 2009-05-15

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

40 enrolled

Dermatologic

Melanoma Neoplasms

NCT00633269 2009-01-14

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

6 enrolled